

EVALUATION OF GP IIB/IIIa INHIBITORS AND BIVALIRUDIN USE IN PERCUTANEOUS CORONARY INTERVENTION AT A UNIVERSITY HOSPITAL (A3), Kevin Hiroo, Patricia Parker. UC Davis Medical Center, Sacramento, CA (kevin.hiroo@ucdmc.ucdavis.edu), IRB approval pending.

The use of glycoprotein (GP) IIB/IIIa inhibitors and bivalirudin during percutaneous coronary intervention (PCI) at the University of California, Davis Medical Center has not been examined since 2000. Since then, new evidence and guidelines have emerged regarding the appropriate use of these agents. This review will help determine the current usage patterns of GP IIB/IIIa inhibitors and bivalirudin compared to the current evidence and guidelines. This study will examine patients receiving abciximab, eptifibatide, and bivalirudin during PCI within a three year time period. Pertinent patient demographics, admission symptoms and diagnosis, past medical history and risk factors, and indications for PCI will be collected from the UC Davis Medical Center's American College of Cardiology Cardiovascular Data Registry. The data collected will be further analyzed in three yearly increments to determine whether or not each agent was utilized in an appropriate manner. These yearly increments may also help to show trends in drug usage. Descriptive statistics and other appropriate statistical methods will be utilized in the data analysis. The results of this study will be discussed.